Upstream Bio, Inc.
About Upstream Bio, Inc.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $2.9M
- Net income
- -$143.4M
- Total assets
- $353.8M
- Market cap
- $383.7M
- Operating margin
- -5618.8%
- Net margin
- -5026.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.9M
- Operating expenses
- $163.2M
- Operating income
- -$160.4M
- Income tax
- $0
- Net income
- -$143.4M
- EPS (basic)
- $-2.66
- EPS (diluted)
- $-2.66
Balance sheet
- Total assets
- $353.8M
- Current assets
- $351.8M
- Total liabilities
- $14.0M
- Current liabilities
- $13.5M
- Shareholders’ equity
- $339.8M
Cash flow
- Operating cash flow
- -$133.3M
- Investing cash flow
- -$93.5M
- Financing cash flow
- $2.4M
- Net cash flow
- -$224.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $383.7M
- EPS (diluted)
- $-2.66
- Shares outstanding
- 59.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 11, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $143.4M in FY2025.
- Revenue grew 20% from FY2024 to FY2025.
- Trading 80% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Upstream Bio, Inc..
Write a review
News about Upstream Bio, Inc.
News & sentiment via Polygon.io
